Browse studies

Find your next paid study

1 recruiting study matching your filters

A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)

This is a Phase Ib in adult patients with relapsed or refractory EBV-positive DLBCL using daily oral dosing of VK-2019 in three dose escalation cohorts: 600 mg…

Diffuse Large B Cell Lymphoma RefractoryDiffuse Large B Cell Lymphoma RelapsedEpstein-Barr Virus (EBV) Infection

Thomas Jefferson UniversityNCT06789159